SUN 13837

Drug Profile

SUN 13837

Alternative Names: SUN-13837

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Asubio Pharmaceuticals
  • Developer Daiichi Sankyo Company
  • Class Small molecules
  • Mechanism of Action Fibroblast growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Spinal cord injuries; Stroke

Most Recent Events

  • 01 Apr 2015 Asubio Pharmaceuticals completes enrolment in a phase II trial in Spinal cord injuries in USA, Canada, Czech Republic, France, Poland and United Kingdom (NCT01502631)
  • 01 Mar 2015 Asubio Pharmaceuticals completes a phase II trial in Spinal cord injuries in USA, Canada, Czech Republic, France, Poland and United Kingdom (NCT01502631)
  • 29 Jan 2015 Discontinued- Phase-II for Stroke in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top